Health Care • Biotechnology: Pharmaceutical Preparations
$20.76 ▲ +0.44
(+2.17%)
MKT CAP: $3.58B • VOL: 2.19M
52W L $18 52W H $31
ACAD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.07B | $957.8M | $726.4M |
| YoY Revenue Growth % | +11.9% | +31.8% | — |
| Gross Profit | $982.5M | $876.0M | — |
| Gross Margin % | 91.7% | 91.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $104.8M | $230.8M | -$73.4M |
| Operating Margin % | 9.8% | 24.1% | -10.1% |
| Net Income (GAAP) | $391.0M | $226.0M | -$61.0M |
| EBITDA (Normalized) | $108.6M | $231.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $109.8M | $157.7M | $16.7M |
| Capital Expenditures (CapEx) | $4.7M | $523.0K | — |
| Free Cash Flow (FCF) | $105.1M | $157.2M | $16.7M |
| FCF Margin % | 9.8% | 16.4% | 2.3% |
| Return on Invested Capital (ROIC %) | 7.9% | 44.1% | — |
| Cash & Short-Term Equivalents | $177.7M | $319.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $1.23B | $732.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ACAD.